GGH inhibitors, or gamma-glutamyl hydrolase inhibitors, belong to a specific chemical class of compounds that play a crucial role in the regulation of the gamma-glutamyl cycle, which is a critical component of amino acid metabolism. These inhibitors are designed to target the enzyme gamma-glutamyl hydrolase, abbreviated as GGH, which is primarily responsible for catalyzing the hydrolysis of gamma-glutamyl compounds. The gamma-glutamyl cycle is a fundamental biochemical pathway involved in the synthesis and degradation of glutathione, a potent antioxidant found in cells throughout the body. GGH inhibitors disrupt this cycle by inhibiting the enzymatic activity of GGH, thereby influencing the levels of gamma-glutamyl compounds and, consequently, altering glutathione metabolism.
Structurally, GGH inhibitors encompass a diverse range of compounds, including small molecules and peptides, each designed to interact with the active site of the GGH enzyme, inhibiting its ability to break down gamma-glutamyl compounds. This interference with GGH's enzymatic activity has far-reaching implications for cellular redox balance, as glutathione is a key player in protecting cells from oxidative damage and maintaining intracellular homeostasis. GGH inhibitors are important tools for researchers studying the complex interplay between glutathione metabolism and various physiological processes.
Items 1 to 10 of 11 total
Display:
Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
---|---|---|---|---|---|---|
Imatinib | 152459-95-5 | sc-267106 sc-267106A sc-267106B | 10 mg 100 mg 1 g | $25.00 $117.00 $209.00 | 27 | |
Inhibits tyrosine kinase activity of BCR-ABL and c-KIT, disrupting signaling pathways in cancer cells. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $56.00 $260.00 $416.00 | 129 | |
Blocks RAF/MEK/ERK and VEGF receptor signaling, inhibiting angiogenesis and tumor cell proliferation. | ||||||
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $62.00 $112.00 $214.00 $342.00 | 74 | |
Selectively inhibits epidermal growth factor receptor (EGFR) tyrosine kinase, impeding tumor growth and progression. | ||||||
Erlotinib Hydrochloride | 183319-69-9 | sc-202154 sc-202154A | 10 mg 25 mg | $74.00 $119.00 | 33 | |
Targets EGFR kinase, preventing autophosphorylation and downstream signaling, hindering cancer cell proliferation. | ||||||
Lapatinib | 231277-92-2 | sc-353658 | 100 mg | $412.00 | 32 | |
Dual inhibition of EGFR and HER2 kinases, hindering their signaling pathways in breast cancer cells. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $47.00 $145.00 | 51 | |
Binds to multiple tyrosine kinases, including BCR-ABL, blocking downstream signaling and inhibiting leukemia cells. | ||||||
Vemurafenib | 918504-65-1 | sc-364643 sc-364643A | 10 mg 50 mg | $115.00 $415.00 | 11 | |
Selective inhibition of mutant BRAF kinase, impairing MAPK signaling and inhibiting melanoma cell growth. | ||||||
Sunitinib, Free Base | 557795-19-4 | sc-396319 sc-396319A | 500 mg 5 g | $150.00 $920.00 | 5 | |
Inhibits multiple receptor tyrosine kinases, including VEGFR and PDGFR, hampering tumor angiogenesis and growth. | ||||||
Nilotinib | 641571-10-0 | sc-202245 sc-202245A | 10 mg 25 mg | $205.00 $405.00 | 9 | |
Potent BCR-ABL inhibitor, suppressing tyrosine kinase activity. | ||||||
Pazopanib | 444731-52-6 | sc-396318 sc-396318A | 25 mg 50 mg | $127.00 $178.00 | 2 | |
Targets VEGFR, PDGFR, and c-KIT kinases, inhibiting angiogenesis and stalling tumor progression. |